ライフサイエンスコーパス: cysteinyl

1 cysteinyl-glycinyl bond of MCTR2 to give 13R-cysteinyl, 14S-hydroxy-4Z,7Z,9E,11E,13R,14S,16Z,19Z-doco

2 the 3-mercaptohexan-1-ol precursors and 4-S-cysteinyl-4-methylpentan-2-one.

3 domain results in the formation of a flavin-cysteinyl adduct (LOV390) which thermally relaxes back t

4 vin protonation, which is common to both the cysteinyl adduct and the NSQ.

5 gen, voltage) protein, couples light-induced cysteinyl adduct formation at the flavin ring to conform

6 hain contributes to stabilization of the C-S cysteinyl adduct.

7 We report a method to enrich cysteinyl adducts of human serum albumin (HSA), represen

8 Elevated cysteinyl adducts to L-DOPA and DOPAC are seen early and

9 rcaptalbumin (i.e., unadducted HSA) from the cysteinyl adducts.

10 However, incubation of the enzyme with the cysteinyl adenylate analogue, 5'-O-[N-(l-cysteinyl)-sulf

11 y 5.2 s-1, respectively, consistent with the cysteinyl adenylate being a kinetically competent interm

12 zes the formation of a kinetically competent cysteinyl-adenylate intermediate after the addition of A

13 The approach utilizes the cysteinyl affinity resin to selectively enrich S-nitrosy

14 utamine forming external aldimine complexes, cysteinyl aldimine and glutaminyl aldimine.

15 othiol, i.e., 1-D-myo-inosityl-2-(N-acetyl-L-cysteinyl)amido-2-deoxy-alpha-D-glucopyranoside (MSH or

16 othiol, i.e., 1-d-myo-inosityl-2-(N-acetyl-l-cysteinyl)amido-2-deoxy-alpha-d-glucopyranoside (MSH or

17 deacetylated, ligated with cysteine, and the cysteinyl amino group acetylated by acetyl-CoA to comple

18 endogenous activity was fully inhibited by a cysteinyl aspartate-specific protease-1-specific inhibit

19 Caspases are cysteinyl-aspartate proteases that function under apopto

20 Molecular modeling predicts formation of a cysteinyl-aurothiomalate adduct at Cys-69 that protrudes

21 de analogues, delta-(l-alpha-aminoadipoyl)-l-cysteinyl-beta-methyl-d-cyclopropylglycine and delta-(l-

22 ists of a [4Fe-4S](H)-subcluster linked by a cysteinyl bridge to a unique organometallic [2Fe](H)-sub

23 muscle cell apoptosis, and MC and AAA lesion cysteinyl cathepsin expression and activities.

24 An imbalance between cysteinyl cathepsins and their principal endogenous inhi

25 Cysteinyl cathepsins have been implicated in multiple ma

26 redox diphenol regeneration and formation of cysteinyl-CGA conjugates, which also contributed to anti

27 Cysteine-cysteinyl chemokine receptor 4 (CCR4) is expressed by a

28 Biosynthetic metabolomes of cysteinyl-containing immunoresolvents.

29 Other cysteinyl-containing lipid mediators (LMs) derived from

30 ylglycine and delta-(l-alpha-aminoadipoyl)-l-cysteinyl-d-cyclopropylglycine, designed as probes for t

31 iol (BSH), the alpha-anomeric glycoside of L-cysteinyl-D-glucosamine with L-malic acid, is a major lo

32 near tripeptide delta-L-alpha-aminoadipoyl-L-cysteinyl-D-valine (ACV) to isopenicillin N (IPN).

33 he tripeptide delta-(l-alpha-aminoadipoyl)-l-cysteinyl-d-valine (ACV).

34 ipeptide (from delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-valine synthetase).

35 LAR converts 4beta-(S-cysteinyl)-epicatechin back to epicatechin, the starter

36 insoluble PAs, and accumulation of 4beta-(S-cysteinyl)-epicatechin, which provides the 4-->8 linked

37 es the endogenous TSOX adduct and known 4a-S-cysteinyl flavin adducts.

38 iron-sulfur cluster ([4Fe-4S](2+)) and a 6-S-cysteinyl flavin mononucleotide (6-S-Cys-FMN) as redox c

39 ore and undergo photochemistry indicative of cysteinyl-flavin adduct formation.

40 ght through the photochemical formation of a cysteinyl-flavin covalent adduct.

41 s the tripeptide glutathione (gamma-glutamyl-cysteinyl-Gly) were found to be strong agonists of the G

42 rved the S-4-mercapto-4-methylpentan-2-one-l-cysteinyl-glycine (CysGly-4MMP) and S-4-mercapto-4-methy

43 rotective thiols (cysteine, glutathione, and cysteinyl-glycine) and lactate from astrocytes.

44 ol-containing tripeptide (l-gamma-glutamyl-l-cysteinyl-glycine) that can function as a reversible red

45 Glutathione (gamma-glutamyl-cysteinyl-glycine, GSH) is a major thiol-containing pept

46 as mediated by dipeptidases that cleaved the cysteinyl-glycinyl bond of MCTR2 to give 13R-cysteinyl,

47 or other thiol-hydroquinones, for example, S-cysteinyl-hydroquinone, as substrates.

48 ilon)-D-cysteinyl-L-lysine, and N(epsilon)-L-cysteinyl-L-lysine into recombinant proteins in Escheric

49 epsilon)-L-thiaprolyl-L-lysine, N(epsilon)-D-cysteinyl-L-lysine, and N(epsilon)-L-cysteinyl-L-lysine

50 We have applied this cysteinyl-labeling assay to the study of platelet-derive

51 We anticipate that this cysteinyl-labeling enrichment strategy can be applied br

52 Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary

53 il infiltration, and increased levels of the cysteinyl leukotriene (cys-LT) leukotriene C(4) (LTC(4))

54 ) C4 synthase (LTC4S), which is required for cysteinyl leukotriene (cys-LT) production.

55 Tryptase and cysteinyl leukotriene (cysLT) levels were measured in na

56 Cysteinyl leukotriene (cysLT) overproduction is a hallma

57 human mast cell line (LUVA) as determined by cysteinyl leukotriene (CysLT) production.

58 We found that both cysteinyl leukotriene (CysLT) receptors, CysLT(1) and Cy

59 model is reversible by administration of the cysteinyl leukotriene (CysLT)1 receptor antagonist monte

60 patients with asthma and may participate in cysteinyl leukotriene (CysLT; C(4), D(4), and E(4)) synt

61 The paracrine signal was identified as a cysteinyl leukotriene because 1) RNAi knockdown or pharm

62 The antioxidant GSH and the pro-inflammatory cysteinyl leukotriene C4 have been identified as key phy

63 Many studies show that the cysteinyl leukotriene cascade remains highly activated i

64 eatment for patients with a highly activated cysteinyl leukotriene cascade.

65 reased mRNA expression of histamine H(1) and cysteinyl leukotriene CysLT(1) receptors.

66 The combination of PGD2 and cysLTs (notably cysteinyl leukotriene E4 [LTE4]) enhances TH2 cytokine p

67 st cell precursors and selectively increased cysteinyl leukotriene formation by mast cells in a manne

68 first time, that the phagosome is a site of cysteinyl leukotriene formation.

69 Cysteinyl leukotriene G protein-coupled receptors CysLT(

70 on the ability of oxidative stress to alter cysteinyl leukotriene generation.

71 ility (RVP) was demonstrated using a bespoke cysteinyl leukotriene induced rodent model.

72 d urinary leukotriene E(4) levels indicating cysteinyl leukotriene inflammation can differentiate LAB

73 ding the production of Th2 cytokines and the cysteinyl leukotriene LTC(4).

74 ompared with their classic substrates in the cysteinyl leukotriene metabolome.

75 polymorphism was associated with changes in cysteinyl leukotriene production, lung function, airway

76 This resulted in further cysteinyl leukotriene production, triggering a positive

77 Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT(1)R) are efficacio

78 oth murine and human fibrocytes express both cysteinyl leukotriene receptor (CysLT) 1 and CysLT2.

79 Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT1R) are widely used

80 Furthermore, LTD4 plus PGE2, through cysteinyl leukotriene receptor 1 (CysLT1R) and E-prostan

81 bute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R).

82 "proatopic" neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced

83 human T(H)2 cells might selectively express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA.

84 We functionally assessed cysteinyl leukotriene receptor 1 protein (CysLT(1)) expr

85 TH2 cells, and montelukast, an antagonist of cysteinyl leukotriene receptor 1.

86 s and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln

87 Stimulation of the cysteinyl leukotriene receptor activated CRAC channels a

88 zed by some as a dualistic uracil nucleotide/cysteinyl leukotriene receptor and by others as inactive

89 stigated the effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatm

90 The use of cysteinyl leukotriene receptor antagonists (LTRAs) for a

91 y, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.

92 ing montelukast (an antagonist of the type 1 cysteinyl leukotriene receptor) also inhibited E. coli i

93 Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) co

94 e inflammatory cells and their expression of cysteinyl leukotriene receptors 1 and 2 (CysLT(1) and Cy

95 antiangiogenic small molecule antagonist of cysteinyl leukotriene receptors 1 and 2 (CysLT1 and CysL

96 rectly target VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1-2) at mi

97 ammatory factor that acts on plasma membrane cysteinyl leukotriene receptors.

98 rus expression, T-cell death, and eosinophil cysteinyl leukotriene release.

99 diating the leukotriene responses in asthma, cysteinyl leukotriene type 1 receptor (CysLT1R), have no

100 inic and H1 histamine receptor and expressed cysteinyl leukotriene type 1 receptor in human embryonic

101 G-protein-coupled cysteinyl leukotriene type I (CysLT1) receptors regulate

102 t cytoplasmic Ca(2+) oscillations induced by cysteinyl leukotriene type I receptor activation run dow

103 ations can be evoked by modest activation of cysteinyl leukotriene type I receptors by the physiologi

104 The cysteinyl leukotriene type I receptors desensitize throu

105 Here, we show that following stimulation of cysteinyl leukotriene type I receptors in rat basophilic

106 3) RNAi knockdown of cysteinyl leukotriene type I receptors on resting cells

107 2) Block of cysteinyl leukotriene type I receptors on resting mast c

108 tion of partner receptors (nucleotide P2Y12, cysteinyl-leukotriene CysLT1) to reconstitute the elusiv

109 s in s/s mice were associated with increased cysteinyl-leukotriene production in vivo and in AMs in v

110 gene encoding the G protein-coupled receptor cysteinyl-leukotriene receptor 2 (CysLTR2).

111 mine H1 receptor antagonist, cetirizine, and cysteinyl-leukotriene receptor antagonist, montelukast,

112 mice could be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.

113 1/2, cytosolic phospholipase A(2) alpha, and cysteinyl-leukotriene synthesis confers resistance to s/

114 educes antigen-induced secretion of PGD2 and cysteinyl-leukotriene.

115 he mast cell mediators histamine (9.0-fold), cysteinyl leukotrienes (4.5-fold), and prostaglandin (PG

116 decreased eicosanoid biosynthesis, including cysteinyl leukotrienes (80% mean decrease) that mediated

117 The cysteinyl leukotrienes (cys-LTs) are a family of potent

118 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory

119 The cysteinyl leukotrienes (cys-LTs) are proinflammatory lip

120 Cysteinyl leukotrienes (cys-LTs) are proinflammatory med

121 The cysteinyl leukotrienes (cys-LTs) are three structurally

122 Cysteinyl leukotrienes (cys-LTs) can mediate Th2 immunit

123 receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils.

124 Cysteinyl leukotrienes (cys-LTs) induce inflammation thr

125 Cysteinyl leukotrienes (cys-LTs) induce inflammatory res

126 The cysteinyl leukotrienes (cys-LTs), leukotriene C4 (LTC4),

127 stimulated a rapid and robust production of cysteinyl leukotrienes (cys-LTs), proinflammatory lipid

128 Although arachidonic acid metabolites, cysteinyl leukotrienes (cys-LTs; leukotriene [LT] C4, LT

129 ion was evaluated as Ca2+ flux, secretion of cysteinyl leukotrienes (CysLT), and eosinophil-derived n

130 In contrast, high levels of cysteinyl leukotrienes (cysLTs) and 12-/15-LOX metabolit

131 Because cysteinyl leukotrienes (cysLTs) are also produced during

132 Cysteinyl leukotrienes (cysLTs) are bronchoconstricting

133 Cysteinyl leukotrienes (cysLTs) are important mediators

134 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs) are lipid mediators deri

135 Cysteinyl leukotrienes (CysLTs) are potent lipid mediato

136 Cysteinyl leukotrienes (CysLTs) are potent prophlogistic

137 Leukotriene E4 (LTE4) the most stable of the cysteinyl leukotrienes (cysLTs) binds poorly to classica

138 Cysteinyl leukotrienes (CysLTs) contribute to asthma pat

139 Cysteinyl leukotrienes (cysLTs) facilitate mucosal type

140 nstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma media

141 Here, we show that tuft cells secrete cysteinyl leukotrienes (cysLTs) to rapidly activate type

142 ctures show that the N-terminal domain binds cysteinyl leukotrienes (cysLTs) with high affinities (50

143 r of the airways, involves overproduction of cysteinyl leukotrienes (cysLTs), activation of airway ma

144 thma, tissue eosinophilia, overproduction of cysteinyl leukotrienes (cysLTs), and respiratory reactio

145 eukotriene E4 (LTE4), the most stable of the cysteinyl leukotrienes (cysLTs), binds poorly to classic

146 Large amounts of cysteinyl leukotrienes (cysLTs), classically known as a

147 In contrast, cysteinyl leukotrienes (cysLTs), important proinflammato

148 Cysteinyl leukotrienes (cysLTs), including leukotriene (

149 The 3 cysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4) (

150 Cysteinyl leukotrienes (cysLTs), leukotriene C4 (LTC4),

151 is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs), which are present in as

152 onstitutive and aspirin-induced secretion of cysteinyl leukotrienes (CysLTs).

153 step in the formation of eicosanoids such as cysteinyl leukotrienes (CysLTs).

154 capable of both producing and responding to cysteinyl leukotrienes (CystLTs), allowing for the killi

155 d lipoxygenase products of arachidonic acid, cysteinyl leukotrienes (LTs), contribute to E. coli K1 i

156 poxygenated metabolites of arachidonic acid, cysteinyl leukotrienes (LTs).

157 lipid inflammatory mediators comprising the cysteinyl leukotrienes (LTs; LTC4, LTD4, and LTE4), only

158 reatments being developed beyond blockade of cysteinyl leukotrienes and IgE and improvements in inhal

159 Cysteinyl leukotrienes and oxidative stress have both be

160 ophagoides farinae through the generation of cysteinyl leukotrienes and proinflammatory cytokines, re

161 , eicosanoids implicated in allergy (such as cysteinyl leukotrienes and prostaglandin D(2)) and the n

162 and suggest downstream provocative roles for cysteinyl leukotrienes and protective roles for SOCS3 in

163 nsible for the scavenging of proinflammatory cysteinyl leukotrienes and thromboxanes at the feeding s

164 AM phagocytosis, killing, and production of cysteinyl leukotrienes and TNF-alpha are restored in the

165 Cysteinyl leukotrienes are established mediators of bron

166 Our findings that cysteinyl leukotrienes are involved in regulating airway

167 Cysteinyl leukotrienes are involved in the pathogenesis

168 Cysteinyl leukotrienes are primarily produced by mast ce

169 lso demonstrate direct binding of U46619 and cysteinyl leukotrienes C(4), D(4) and E(4) to the P. pap

170 feedback cascade involving CRAC channels and cysteinyl leukotrienes constitute a novel mechanism for

171 Cysteinyl leukotrienes contribute to Th2-type inflammato

172 Cysteinyl leukotrienes D(4) and E(4) and PGD(2) also ind

173 Herein we report that uracil nucleotides and cysteinyl leukotrienes do not activate human, mouse, or

174 Measurement of the release of histamine and cysteinyl leukotrienes documented that this bronchoprote

175 Using immunostaining for the cysteinyl leukotrienes in carbodiimide-fixed cells, we s

176 We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficki

177 entify previously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary traff

178 farinae-elicited IL-6, IL-23, TNF-alpha, and cysteinyl leukotrienes in the lung.

179 combination of antagonists of histamine and cysteinyl leukotrienes in the presence of indomethacin.

180 ccompanied by a surge in bronchoconstrictory cysteinyl leukotrienes produced at the expense of LTB4 i

181 We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cel

182 bstance of anaphylaxis was composed of three cysteinyl leukotrienes that act in the inflammatory resp

183 al protists, stimulate tuft cells to release cysteinyl leukotrienes to amplify anti-helminth immunity

184 ut the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the t

185 ablysin-15 was found to bind proinflammatory cysteinyl leukotrienes with submicromolar affinities.

186 Prominent among such signals are the cysteinyl leukotrienes, a family of potent proinflammato

187 ncreases in metabolites of prostaglandin D2, cysteinyl leukotrienes, and isoprostanes following the c

188 to produce LTC4, the parent compound of the cysteinyl leukotrienes, important mediators of asthma.

189 , ATLa treatment led to marked reductions in cysteinyl leukotrienes, interleukin-4 (IL-4), and IL-10,

190 cts: 5-,12-,15-hydroxyeicosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thro

191 Pharmacological inhibition of cysteinyl leukotrienes, lipoxygenated products of arachi

192 triad of preclinical areas of investigation-cysteinyl leukotrienes, mast cells, and complement-with

193 The de novo synthesis of cysteinyl leukotrienes, TNFalpha, CXCL8, CCL2, CCL3, and

194 LTC4 is the parent molecule of the cysteinyl leukotrienes, which are recognized for their p

195 cterise the responsiveness of human P2Y12 to cysteinyl leukotrienes.

196 ial killing, and production of TNF-alpha and cysteinyl leukotrienes.

197 , whereas mRECs produced both LTB(4) and the cysteinyl leukotrienes.

198 nflux through CRAC channels and responded to cysteinyl leukotrienes.

199 ntrast, M1 macrophages gave higher levels of cysteinyl leukotrienes.

200 piratory tissues and excessive production of cysteinyl leukotrienes.

201 -IgE or SCF and the generation of histamine, cysteinyl-leukotrienes (cys-LTs) and prostaglandin D(2)

202 itis model accompanied by impaired levels of cysteinyl-leukotrienes and prostaglandin E2.

203 The synthesis of cysteinyl-leukotrienes was reduced and that of PGE(2) en

204 classes of molecules: uracil-nucleotides and cysteinyl-leukotrienes.

205 re, where a ferric ion and four coordinating cysteinyl ligands are arranged into a distorted tetrahed

206 NOEs between the beta-CH(2) protons of Zn cysteinyl ligands are consistent with a strand-swapped H

207 enzymes and supports the involvement of non-cysteinyl ligands in the coordination of auxiliary clust

208 different) single histidine ligands, or only cysteinyl ligands is possible in the same protein fold.

209 -4S](2+) cluster that is coordinated by four cysteinyl ligands, two of which are adjacent in the amin

210 [4Fe-4S] cluster cofactor with a unique, non-cysteinyl-ligated, iron ion (Fea), which is proposed to

211 ditional requirement for a catalytic base in cysteinyl ligation.

212 y in the literature for analyzing interchain cysteinyl-linked ADCs are either not amenable to online

213 nce method for quality control of interchain cysteinyl-linked ADCs.

214 omic profiling showed that the most abundant cysteinyl LMs in healthy human lungs were MCTRs, whereas

215 of B leukotriene type 1 (BLT1) receptor and cysteinyl LT type 1 (cysLT1) receptor, respectively.

216 C(4) synthase, LTB(4) receptors 1 and 2, and cysteinyl-LT receptors 1 and 2.

217 es (LTs) C4, D4, and E4, collectively termed cysteinyl LTs (cysLTs), are lipid mediators formed by th

218 demonstrated in vivo for LTB(4), but not for cysteinyl LTs (cysLTs).

219 teinyl LTs, suggesting that cPLA(2)alpha and cysteinyl LTs contribute to type III GBS invasion of the

220 ific host factors involving cPLA(2)alpha and cysteinyl LTs contribute to type III GBS penetration of

221 m subjects with AERD generated more LTB4 and cysteinyl LTs than did granulocytes from controls with a

222 abolished by inhibition of cPLA(2)alpha and cysteinyl LTs, suggesting that cPLA(2)alpha and cysteiny

223 e enhanced accumulation of LTB(4) but not of cysteinyl-LTs.

224 The cysteinyl moiety at position 1 of the C-TAT peptide cont

225 ves the two-electron oxidation of a specific cysteinyl or seryl residue on the relevant sulfatase.

226 erminal peptide thioester with an N-terminal cysteinyl peptide to produce a native peptide bond betwe

227 a functionally competent reducing agent for cysteinyl persulfide bond cleavage, releasing inorganic

228 ect the mechanism of formation of the enzyme cysteinyl persulfide intermediate in the reaction of a c

229 with the light-induced formation of a flavin-cysteinyl photoadduct.

230 sed cathepsin K immunostaining and increased cysteinyl proteinase activity using near infrared fluore

231 radical (Y(122)*) in R2 generate a transient cysteinyl radical (C(439)*) in R1 through a pathway thou

232 es a cysteine residue in the R1 subunit to a cysteinyl radical (C*), which abstracts the 3'-hydrogen

233 Turnover requires formation of a cysteinyl radical (C439*) in the active site of alpha2 a

234 lectron from a cysteine residue to produce a cysteinyl radical.

235 Resultant cysteinyl radicals are subject to post-translational mod

236 In mitochondrial complex I, specific cysteinyl redox domains modulate ROS production from the

237 AO A contains a flavin covalently bound to a cysteinyl residue at C8alpha.

238 odification(s) of Cys-122, a beta(1)-subunit cysteinyl residue demonstrated previously to modulate NO

239 ng that the active metabolite is linked to a cysteinyl residue of CYP2B6 via a disulfide bond.

240 opidogrel and the covalent modification of a cysteinyl residue of human cytochrome P450 2B6 in a reco

241 e) catalyzes the two-electron oxidation of a cysteinyl residue on a cognate protein to a formylglycyl

242 pacer segments was achieved through a unique cysteinyl residue.

243 re acylated with a (S)-(2,3-bisacyloxypropyl)cysteinyl residue.

244 ure to acidic pH; thus, modification of free cysteinyl residues biochemically separated the process o

245 Cysteinyl residues important for Cu(I) binding are also

246 or separation and identification of modified cysteinyl residues in proteins have been developed, crit

247 Furthermore, mutation of key cysteinyl residues ligating the catalytic [Fe4S4] cluste

248 hes were used to assess the pK(a) of the two cysteinyl residues of AhpC.

249 This analysis identified cysteinyl residues of E1 and E2, which were found to be

250 Here we report studies on the reactivity of cysteinyl residues of the catalytic domain of PHD2 using

251 Among the seven cysteinyl residues of the PHD2 catalytic domain, Cys201

252 Site-directed mutagenesis of cysteinyl residues putatively required as ligands of the

253 This suggests that the modification of free cysteinyl residues results in the loss of infectivity by

254 pepsin at pH 2, a limited transfer to other cysteinyl residues was observed.

255 nature of this disulfide network, E1 and E2 cysteinyl residues were labeled with iodoacetamide in th

256 These species can harm/destroy cysteinyl residues, iron-sulphur clusters, DNA and polyu

257 bonds formed by protein backbone amides with cysteinyl S(gamma) atoms play important roles in modulat

258 Cysteinyl S-nitrosylation has emerged as an important po

259 t of LP-BM5-infected mice with N-(N-acetyl-l-cysteinyl)-S-acetylcysteamine (I-152), an N-acetyl-cyste

260 he N-acetyl-p-benzoquinoneimine metabolite L-cysteinyl-S-acetaminophen was detected in the mouse spin

261 by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine (PAM(2)CS) compounds are potential va

262 -S-(2,3-bis(palmitoyloxy)-(2R,S)-propyl)-(R)-cysteinyl-seryl-(l ysyl)3-lysine (Pam3CysSK4), a synthet

263 prepare circular proteins with or without a cysteinyl side chain.

264 structural consequences of their binding to cysteinyl side chains in proteins, remain poorly underst

265 g that the pro-S hydrogen atom of the normal cysteinyl substrate is stereoselectively removed during

266 ght binding bisubstrate analogue, 5'-O-[N-(L-cysteinyl)sulfamonyl]adenosine (CSA), has suggested spec

267 A stable bisubstrate analogue, 5'-O-[N-(l-cysteinyl)sulfamonyl]adenosine, exhibits competitive inh

268 the cysteinyl adenylate analogue, 5'-O-[N-(l-cysteinyl)-sulfamonyl]adenosine (CSA), followed by a 24-

269 llagen 4-hydroxyproline content and enhanced cysteinyl sulfenic acid modification of ER proteins.

270 st that reduction-oxidation modifications of cysteinyl sulfhydryl groups in mature ADAM17 may serve a

271 itions of increased oxidant stress confirmed cysteinyl sulfinic acid (m/z 435), sulfonic acid (m/z 44

272 tachment; (ii) to spatially position the two cysteinyl sulfurs adjacent to the two heme vinyl groups

273 onstrate that aldosterone modulates an ET(B) cysteinyl thiol redox switch to decrease pulmonary endot

274 They further indicate that H bonds to the cysteinyl thiolate sulfur ligand reduce the spin density

275 ecies production, which oxidatively modified cysteinyl thiols in the eNOS-activating region of ET(B)

276 Quantitation of the redox status of cysteinyl thiols within ER-DBD employed cysteine-specifi

277 o coordinate 7 Zn(2+) or Cd(2+) ions with 20 cysteinyl thiols, will bind 8 structurally significant C

278 Cysteinyl-tRNA synthetase (CARS) encodes the enzyme that

279 for protein synthesis using both a canonical cysteinyl-tRNA synthetase (CysRS) as well as a set of tw

280 Human cysteinyl-tRNA synthetase (CysRS) does not associate wit

281 of Sec at Cys codons due to the inability of cysteinyl-tRNA synthetase (CysRS) to discriminate agains

282 Cys)) in methanogens that lack the canonical cysteinyl-tRNA synthetase (CysRS).

283 synthetase (proS [mhp397]) (P = 0.009), and cysteinyl-tRNA synthetase (cysS [mhp661]) (P < 0.001) we

284 ynthetases SepRS (forming Sep-tRNA(Cys)) and cysteinyl-tRNA synthetase (forming Cys-tRNA(Cys)).

285 on factor 2, cell division protein FtsZ, and cysteinyl-tRNA synthetase as immunoreactive proteins.

286 association was also identified at the CARS (cysteinyl-tRNA synthetase) locus (OR = 1.36, P = 3.1 x 1

287 ance system involving a plasmid-encoded CysS cysteinyl-tRNA synthetase, highlighting the power of lar

288 with phosphoserine (Sep), and the well known cysteinyl-tRNA synthetase, which charges the same tRNA w

289 tertiary fold of MshC is similar to that of cysteinyl-tRNA synthetase, with a Rossmann fold catalyti

290 ction catalyzed by prokaryotic and mammalian cysteinyl-tRNA synthetases (CARSs).

291 that is unique to several halophile archaeal cysteinyl-tRNA synthetases (CysRS), which catalyze attac

292 uggests similarities and differences between cysteinyl-tRNA synthetases and MshC in recognition of th

293 of tRNA-bound O-phosphoserine (Sep) to form cysteinyl-tRNA(Cys) (Cys-tRNA(Cys)) in methanogens that

294 ubset of methanogenic archaea synthesize the cysteinyl-tRNA(Cys) (Cys-tRNA(Cys)) needed for protein s

295 Synthesis of cysteinyl-tRNA(Cys) in methanogenic archaea proceeds by

296 sS, which converts phosphoseryl-tRNA(Cys) to cysteinyl-tRNA(Cys) in nearly all methanogens.

297 teine to tRNA(Cys) to generate the essential cysteinyl-tRNA(Cys) required for protein synthesis.

298 ar iron center and the catalytic role of the cysteinyl-tyrosine linkage.

299 Cysteinyl variants on the alpha3 and L3 regions, which f

300 with the intrinsic reactivity of Cys-SSH for cysteinyl versus sulfur transfer, are consistent with th